Kestra Medical Technologies (KMTS) Cost of Revenue (2024 - 2026)

Kestra Medical Technologies (KMTS) has reported Cost of Revenue for 3 consecutive years, with $13.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cost of Revenue rose 34.96% year-over-year to $13.0 million; the TTM figure through Apr 2026 stood at $46.3 million (up 29.93% YoY), while the FY2026 annual figure was $46.3 million, up 29.93% from the prior year.
• Cost of Revenue climbed to $13.0 million in Q2 2026 per KMTS's latest filing, from $11.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $13.0 million in Q2 2026 and bottomed at $7.4 million in Q1 2024.
• Historically, Cost of Revenue has averaged $9.8 million across 3 years, with a median of $9.2 million in 2024.
• Annual changes were most pronounced in 2025 — Cost of Revenue increased 10.89% — and 2026, when it jumped 36.32%.
• Kestra Medical Technologies' Cost of Revenue stood at $8.9 million in 2024, then grew by 25.46% to $11.1 million in 2025, then climbed by 16.29% to $13.0 million in 2026.
• Business Quant data shows KMTS's Cost of Revenue at $13.0 million in Q2 2026, $11.6 million in Q1 2026, and $11.1 million in Q4 2025.